Cholesterol Clinical Trials

113 recruitingLast updated: June 18, 2026

There are 113 actively recruiting cholesterol clinical trials across 52 countries. Studies span Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2, Early Phase 1. Top locations include Beijing, Beijing Municipality, China, Seoul, South Korea, London, United Kingdom. Updated daily from ClinicalTrials.gov.


Cholesterol Trials at a Glance

113 actively recruiting trials for cholesterol are listed on ClinicalTrialsFinder across 6 cities in 52 countries. The largest study group is Not Applicable with 37 trials, with the heaviest enrollment activity in Beijing, Seoul, and London. Lead sponsors running cholesterol studies include Novartis Pharmaceuticals, Federico II University, and Benjamin Viglianti.

Browse cholesterol trials by phase

Treatments under study

About Cholesterol Clinical Trials

Looking for clinical trials for Cholesterol? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cholesterol trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cholesterol clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 113 trials

Recruiting

Causes and Natural History of Dyslipidemias

AtherosclerosisHypercholesterolemia
National Heart, Lung, and Blood Institute (NHLBI)2,000 enrolled1 locationNCT00353782
Recruiting
Not Applicable

Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

Cardiovascular DiseasesAtherosclerosisDyslipidemia+2 more
Yonsei University1,952 enrolled1 locationNCT07524101
Recruiting

A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

mixed dyslipidemiaPrimary Hypercholesterolemiia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company2,000 enrolled163 locationsNCT06686615
Recruiting
Phase 3

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals60 enrolled43 locationsNCT07037771
Recruiting
Phase 2

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

Hypercholesterolemia
Regeneron Pharmaceuticals420 enrolled6 locationsNCT07477704
Recruiting
Phase 3

Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days

Hypercholesterolaemiamixed dyslipidemia
A. Menarini International Licensing S.A.426 enrolled1 locationNCT07614958
Recruiting
Phase 1

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

Premature Coronary Heart DiseaseHeterozygous Familial Hypercholesterolemia
Verve Therapeutics, Inc.85 enrolled23 locationsNCT06164730
Recruiting
Phase 4

Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention

Atherosclerotic Cardiovascular Disease (ASCVD)Hypercholesterolemia
University Medical Centre Ljubljana60 enrolled1 locationNCT07581808
Recruiting
Phase 2Phase 3

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

Heterozygous Familial Hypercholesterolemia (HeFH)
Merck Sharp & Dohme LLC153 enrolled30 locationsNCT07058077
Recruiting
Phase 2

A Dose-exploration Study of EDP167 in HoFH

Homozygous Familial Hypercholesterolemia (HoFH)
Eddingpharm (Zhuhai) Co., Ltd.20 enrolled1 locationNCT07489209
Recruiting
Phase 1

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

HypercholesterolaemiaMetabolic DiseaseDyslipidemias+7 more
CRISPR Therapeutics AG90 enrolled18 locationsNCT07491172
Recruiting
Phase 3

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

Heterozygous or Homozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals195 enrolled52 locationsNCT05682378
Recruiting

Child-Parent Familial Hypercholesterolemia Screening

Familial Hypercholesterolemia
Children's Hospital of Fudan University15,000 enrolled6 locationsNCT04529967
Recruiting
Phase 3

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Familial Hypercholesterolemia - Heterozygous
Novartis Pharmaceuticals60 enrolled66 locationsNCT06597019
Recruiting

Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

Homozygous Familial Hypercholesterolemia (HoFH)Coronary Computed Tomography Angiography
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)52 enrolled13 locationsNCT07447648
Recruiting

National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry

Sudden Cardiac DeathArrhythmogenic Right Ventricular DysplasiaCardiomyopathy, Dilated+11 more
Hospital do Coracao1,211 enrolled27 locationsNCT06546137
Recruiting
Phase 2

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

Familial Hypercholesterolemia
Vanderbilt University Medical Center72 enrolled1 locationNCT04941599
Recruiting
Phase 1

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

HypercholesterolemiaHypertriglyceridemiaRefractory Hyperlipidemia
Verve Therapeutics, Inc.36 enrolled10 locationsNCT06451770
Recruiting
Not Applicable

Assessing the Effects of Corn and Avocado Oils on the Cardiometabolic Risk Factor Profile

Hypercholesterolemia
Midwest Center for Metabolic and Cardiovascular Research54 enrolled1 locationNCT07514663
Recruiting

Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

Heterozygous Familial HypercholesterolemiaAtherosclerotic Vascular Disease
Novartis Pharmaceuticals200 enrolled20 locationsNCT06958315